Form 4: BioCardia CEO Peter Altman Boosts Stake with Share Purchases

BioCardia Inc.'s President and CEO, Peter Altman, increased his direct ownership in the company by purchasing additional common stock on March 24 and 25, 2026.

Summary

• Peter Altman, President and CEO of BioCardia, Inc. and a Director, acquired 600 shares of common stock on March 24, 2026.
• The shares were purchased at a weighted average price of $1.24 per share, with trades ranging from $1.24 to $1.26.
• An additional 300 shares of common stock were acquired by Peter Altman on March 25, 2026.
• These shares were purchased at a weighted average price of $1.22 per share, with trades ranging from $1.19 to $1.25.
• Following these transactions, Peter Altman directly beneficially owns a total of 274,766 shares of BioCardia, Inc. common stock.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal. Direct share purchases by a CEO demonstrate conviction in the company's value and future prospects, which typically instills confidence among investors.

Positives

• Insider buying by the President and CEO signals confidence in the company's future prospects and valuation.
• The direct purchase of shares aligns management's interests more closely with those of shareholders.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that insider buying, particularly by a CEO, is often interpreted by the market as a positive signal, indicating that management believes the company's stock is undervalued or that significant positive developments are anticipated. This action by BioCardia's CEO could be seen as a vote of confidence in the company's ongoing clinical programs or strategic direction within the competitive biotechnology sector.

Related Party Transactions

• Peter Altman, President and CEO of BioCardia, Inc., purchased 900 shares of the company's common stock over two days, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view the CEO's increased stake as a positive indicator of management's belief in the company's long-term value, potentially boosting investor confidence.
• Employees might perceive this as a sign of stability and positive outlook from leadership.

Key Dates

Recommendation

The direct purchase of common stock by Peter Altman, the President and CEO of BioCardia, Inc., is a strong signal of insider confidence. Such actions typically indicate that management believes the company's shares are undervalued or that significant positive developments are on the horizon. For a seasoned investor, this insider buying suggests a favorable outlook and warrants a 'buy' recommendation, especially when considering the alignment of management's interests with shareholders.

Keywords

BioCardia, BCDA, Peter Altman, Insider Trading, Form 4, Share Purchase, CEO, Director, Common Stock, Biotechnology